# Petrelintide Dosing Guide: Once-Weekly Amylin Analog Titration
> Note: PeptIQ is not a medical provider. Petrelintide is investigational. Exact milligram labels for all Phase 2 arms may remain partially masked in topline releases — do not invent DIY doses from forum posts. Educational content only.
Petrelintide is a long-acting human amylin analog from Roche/Genentech and Zealand Pharma. It sits in the same strategic lane as cagrilintide and eloralintide: weekly satiety biology that is related to, but distinct from, GLP-1.
Quick Answer: How Is Petrelintide Dosed?
From public ZUPREME-1 communications:
| Design element | What was tested |
|---|---|
| Route | Subcutaneous |
| Cadence | Once weekly |
| Arms | Five active dose levels + placebo |
| Escalation | Dose increased about every 4 weeks |
| Primary efficacy window highlighted | Weight change at week 28 (all arms beat placebo) |
| Longer readout | Through week 42, with additional follow-up planned for congress presentation |
Topline coverage has emphasized efficacy and tolerability more than publishing a full public milligram table for every arm. Until the full congress dataset posts dose-by-dose mg, treat "five weekly arms + q4w escalation" as the accurate dosing vocabulary.
ZUPREME-1 Results Snapshot
ZUPREME-1 enrolled 493 adults with overweight or obesity (mean BMI ~37), in a relatively gender-balanced cohort, on lifestyle counseling plus weekly petrelintide or placebo.
Public ADA / Healio-style summaries reported:
- Clinically meaningful weight loss in every active arm vs placebo at the primary 28-week analysis
- At 42 weeks, weight loss up to about 10.7% at the highest petrelintide dose vs about 1.7% placebo
- Investigators highlighted a very well tolerated profile relative to typical GLP-1 expectations in early commentary
That combination — solid double-digit loss with a tolerability narrative — is why petrelintide searches are climbing beside eloralintide and CagriSema.
Why Escalation Every 4 Weeks Matters
Amylin agonists share a GI / early-fullness risk with incretins. A four-week step schedule is the same titration philosophy that works for orforglipron and many GLP-1 labels:
- Start low enough to adapt
- Hold each step long enough to read nausea and meal-size collapse
- Only then climb
- Protect protein and training the whole way
If you are building a tracking template for any future labeled amylin analog, copy that cadence into your log even before milligrams are public.
Petrelintide vs Other Amylin-Lane Drugs
| Compound | Sponsor story | Dosing vibe in public data |
|---|---|---|
| Petrelintide | Roche / Zealand | Weekly SC, 5 Phase 2 arms, q4w escalation |
| Eloralintide | Lilly | Weekly SC, Phase 2 1–9 mg map published |
| Cagrilintide | Novo (CagriSema) | 2.4 mg with semaglutide 2.4 mg in key combo data |
| Amycretin | Novo | Unimolecular GLP-1 + amylin (oral daily / SC weekly programs) |
Petrelintide's near-term differentiator in media coverage is tolerability positioning, not "highest percent loss at all costs."
Pipeline Next Steps to Watch
- Full ZUPREME-1 dose tables + body-composition secondary endpoints at congress
- ZUPREME-2 topline in obesity/overweight with type 2 diabetes (expected later in 2026 per Roche)
- Phase 2 combo exploration with CT-388 (Roche incretin asset) later in 2026
Combo work is the stacking SEO angle: amylin + incretin, same thesis as CagriSema / eloralintide add-on trials.
What to Track
- Weekly injection day
- Escalation week number (every 4th week logic)
- Nausea / early fullness scores for 72 hours post-dose
- Protein grams and lifting sessions
- 7-day average weight + waist
- Reasons for holds (GI, travel, plateau review)
FAQ
Q: What is the standard petrelintide dose?
A: There is no approved consumer dose. Phase 2 used five once-weekly dose levels with escalation about every four weeks. Exact mg per arm should be taken from the full peer-reviewed / congress tables when published.
Q: How much weight loss does petrelintide cause?
A: Public ZUPREME-1 summaries cite up to ~10.7% mean loss at 42 weeks at the highest dose vs ~1.7% placebo. Individual results vary.
Q: Is petrelintide a GLP-1?
A: No. It is an amylin analog. It may feel "GLP-1-like" in appetite effects, but the receptor biology differs.
Q: Can I buy petrelintide as a research peptide?
A: Treat gray-market labels as high-risk and non-equivalent to clinical trial product. Evidence tier and legality first.
Bottom Line
Petrelintide dosing in 2026 public science means: once-weekly SC amylin analog, five Phase 2 dose arms, escalation about every four weeks, and up to ~10.7% mean weight loss at 42 weeks with a strong tolerability narrative. Log the titration logic now; fill milligrams from primary sources when they publish.
Download PeptIQ to track weekly amylin-style protocols with symptom scores.
Educational content only. Not medical advice.
